Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma

被引:30
作者
Pettengell, R [1 ]
Linch, D [1 ]
机构
[1] St George Hosp, Sch Med, Dept Haematol, London SW17 0RE, England
关键词
rituximab; diffuse large B-cell lymphoma; aggressive non-Hodgkin's lymphoma; monoclonal antibody therapy;
D O I
10.1046/j.1365-2141.2003.04274.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The available data on rituximab in combination with chemotherapy confirm that the addition of an independently active biological agent to full-dose standard chemotherapy results in higher rates of complete response, lower rates of relapse, prolonged survival, little additional toxicity and no compromise of the dose intensity of standard chemotherapy regardless of age and risk group. Given the strength of these data, the British Committee for Standards in Haematology believes that rituximab should be available for prescription by UK haematologists and oncologists according to its licensed indication in patients with diffuse large B-cell lymphoma until further data are available to confirm or refute these results. We consider that the use of rituximab with chemotherapy in aggressive lymphoma is cost-effective and that failure to support its introduction will be strongly in conflict with professional and patient opinion.
引用
收藏
页码:44 / 48
页数:5
相关论文
共 30 条
  • [1] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
    Berinstein, NL
    Grillo-Lopez, AJ
    White, CA
    Bence-Bruckler, I
    Maloney, D
    Czuczman, M
    Green, D
    Rosenberg, J
    McLaughlin, P
    Shen, D
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (09) : 995 - 1001
  • [2] Bruno G, 2000, BLOOD, V96, p796A
  • [3] Buckstein R, 1999, SEMIN ONCOL, V26, P115
  • [4] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [5] Coiffier B, 1998, BLOOD, V92, P1927
  • [6] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    Czuczman, MS
    Grillo-López, AJ
    White, CA
    Saleh, M
    Gordon, L
    LoBuglio, AF
    Jonas, C
    Klippenstein, D
    Dallaire, B
    Varns, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 268 - 276
  • [7] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    Demidem, A
    Lam, T
    Alas, S
    Hariharan, K
    Hanna, N
    Bonavida, B
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) : 177 - 186
  • [8] EFFECT OF AGE ON THERAPEUTIC OUTCOME IN ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE
    DIXON, DO
    NEILAN, B
    JONES, SE
    LIPSCHITZ, DA
    MILLER, TP
    GROZEA, PN
    WILSON, HE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) : 295 - 305
  • [9] ELIAS L, 1978, CANCER, V42, P1705, DOI 10.1002/1097-0142(197810)42:4<1705::AID-CNCR2820420408>3.0.CO
  • [10] 2-P